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Abstract
Background: Various factors are related to the occurrence of postoperative pancreatic fistula (POPF)
following pancreatoduodenectomy (PD). Some of the strongest are identified intra- or postoperatively,
which limits their utility in predicting this complication. The preoperative prediction of POPF permits an
individualized approach to patient consent and selection, and may influence postoperative management.
This study sought to develop and test a score to predict POPF.
Methods: A post hoc analysis of a prospectively maintained database was conducted. Consecutive
patients were randomly selected to modelling and validation sets at a ratio of 2 : 1, respectively. Patient
data, preoperative blood tests and physical characteristics of the gland (assessed from preoperative
computed tomography images) were subjected to univariate and multivariate analysis in the modelling set
of patients. A score predictive of POPF was designed and tested in the validation set.
Results: Postoperative pancreatic fistula occurred in 77 of 325 (23.7%) patients. The occurrence of
POPF was associated with 12 factors. On multivariate analysis, body mass index and pancreatic duct
width were independently associated with POPF. A risk score to predict POPF was designed (area under
the receiver operating characteristic curve: 0.832, 95% confidence interval 0.768–0.897; P < 0.001) and
successfully tested upon the validation set.
Conclusions: Preoperative assessment of a patient's risk for POPF is possible using simple measure-
ments. The present risk score is a valid tool with which to predict POPF in patients undergoing PD.
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Introduction
The centralization of pancreatoduodenectomy (PD) procedures
into high-volume centres has reduced perioperative mortality.1–4
Morbidity, however, remains high and affects 16–41% of patients,
even in specialist units.3,5–7 The occurrence of a postoperative
pancreatic fistula (POPF) is a major contributor to both morbid-
ity and mortality. The importance of POPF has been recognized
and, in order to facilitate the auditing of outcomes, comparisons
between centres performing PD and studies reviewing PD, the
International Study Group for Pancreatic Fistula (ISGPF) has
defined three grades of POPF.8 Various interventions (such as
techniques of visceral reconstruction and abdominal drainage)
and therapeutic drugs (such as somatostatin analogues) aimed at
decreasing rates of POPF have been subject to review.9–13 These
meta-analyses do not support a protective role against the devel-
opment of clinically significant POPF.
In the absence of effective strategies to decrease the incidence
of POPF, it is important to identify risk factors for its occur-
rence. Patient characteristics associated with POPF include
increased body mass index (BMI), advanced age, male sex and
comorbidity.14–18 Further factors that may predict POPF are the
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findings of preoperative biochemical tests, but these have been less
thoroughly investigated. A study of 2894 patients found elevated
urea and low albumin to be predictive of postoperative complica-
tions.19 However, this study did not define these complications
and predated the ISGPF definition of POPF. A more recent study
identified high levels of both haemoglobin and sodium to be
associated with POPF as defined by the ISGPF.20 A further variable
attracting increasing attention is pancreatic steatosis, a significant
risk factor for POPF.14,17,18 However, this can only be identified at
pathological assessment and thus has no role in preoperative risk
analysis. Other factors that relate to POPF and can be identified at
preoperative imaging include the pancreas gland width, duct
width, and visceral and superficial fat thickness.16,20–23 Providing
an individualized assessment of POPF risk in the preoperative
phase would facilitate the provision of accurate patient counsel-
ling and obtaining of consent, and might alter aspects of clinical
management such as patient selection for PD, the timing of drain
removal and the instigation of early enteral feeding.
The aim of this study was to review patient factors that may
relate to POPF in order to design a preoperative predictive risk
score for POPF in patients undergoing PD.
Materials and methods
Consecutive patients undergoing PD at a single centre [University
Hospitals Birmingham National Health Service (NHS) Trust, Bir-
mingham, UK] between February 2007 and February 2012 were
identified from a prospectively maintained database. Patients for
whom preoperative computed tomography (CT) imaging was
unavailable were excluded from the study.
All patients underwent PD performed or supervised by a con-
sultant hepatopancreatobiliary surgeon. Whether a pancreato-
jejunostomy (PJ) or pancreatogastrostomy (PG) was performed
depended upon which surgeon performed the procedure. This
decision was not made intraoperatively and reflects each surgeon’s
individual preferred technique of pancreatic anastomosis. Pancre-
atic duct stenting was not performed. A single tube drain was
placed posterior to the hepaticojejunostomy and adjacent to the
PJ or PG anastomosis via the right flank in each patient. Patients
received 100 μg of a subcutaneous somatostatin analogue,
octreotide, three times daily for the first 5 days postoperatively. A
feeding nasojejunal tube was placed in each patient under a stand-
ard protocol to administer feed from the first postoperative day.
Drain fluid amylase levels were assessed on postoperative day 5
and, if the patient was clinically well without biochemical
evidence of POPF, the drain was removed and enteral feeding
instigated.
Data gathered for each patient referred to patient variables
including: gender; age; smoking history; comorbidity; BMI, and
pathological diagnosis (pancreatic adenocarcinoma, cholangio-
carcinoma, ampullary carcinoma, duodenal carcinoma, neuro-
endocrine tumour, intraductal papillary mucinous neoplasm,
pancreatitis, other).
Data on preoperative biochemical results included: white cell
count (WCC); haemoglobin; platelet count; international nor-
malized ratio (INR); aspartate transaminase (AST); alanine
transaminase (ALT); alkaline phosphatase (ALP); sodium; potas-
sium; urea; creatinine; bilirubin; albumin, and neutrophil to lym-
phocyte ratio (NLR). Values immediately preceding the PD were
recorded. The values were considered as continuous data.
Data on the surgical technique used included details of whether
a pylorus-preserving PD or a classic Whipple procedure was con-
ducted, and whether a PJ or a PG was performed.
Preoperative CT imaging was assessed. The sequence of slices
1 mm in thickness was selected for review. Data collected referred
to the anteroposterior thickness of the pancreas gland and the
width of the pancreatic duct (both obtained at the level of the
confluence of the superior mesenteric and portal veins), and to
the anteroposterior thickness of the superficial fat adjacent to the
umbilicus and the anteroposterior thickness of the perirenal fat at
the level of the left umbilical vein. Each measurement was rec-
orded in triplicate and the values were averaged. Measurements
were obtained by a single researcher (KJR) blinded to the patient’s
clinical outcome. A second researcher (a hepatobiliary radiologist,
HM) reviewed the images for a random selection of 50 patients
and recorded the same measurements. The comparison of the
two sets of measurements provided an assessment of intraclass
correlation.
Postoperative pancreatic fistula was defined and classified
according to the ISGPF definition into Grades A, B and C.8
Statistical analysis
Initially, the patient group was randomly divided into two sets at
a ratio of 2 : 1 by an independent statistician. The larger of the two
sets, the ‘modelling set’, was used to produce a risk scoring model,
which was then applied to the smaller ‘validation set’ in order to
validate its predictive accuracy.
To produce the risk score, each of the potential predictors were
first considered univariably for the data in the modelling set. For
the categorical variables, Fisher’s exact test was used to compare
rates of pancreatic leak across the different levels of the factor.
Received operating characteristic (ROC) curves were produced
for the continuous variables to ascertain whether they were sig-
nificant predictors of POPF. The factors found to be significant at
this stage of the analysis were then entered simultaneously into a
backwards stepwise binary logistic regression. The resulting
model was then converted into a risk score.
The new risk score was then applied to the data in the validation
set. An ROC curve was produced to test whether the score
remained a significant predictor of POPF in this second set of
data. The modelling and validation sets were then divided into
deciles and quintiles, respectively, based on the risk score, and the
actual rates of POPF in each category calculated. This allowed the
relationship between the risk score and actual patient outcomes to
be compared graphically.
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Data describing the cohorts were expressed as the median
(interquartile range). The Mann–Whitney U-test and chi-squared
test were used to explore cohort characteristics.
Statistical tests were two-tailed. A P-value of <0.05 was accepted
as indicative of statistical significance. All analyses were performed
using IBM spss Version 19.0 (IBM Corp., Armonk, NY, USA). A
medical statistician (JH) provided advice during the study design,
and performed the analyses and modelling.
Results
A total of 325 patients were included in the study; 217 patients
were randomly selected into the modelling set and the remaining
108 were selected into the validation set. Table 1 describes the
whole cohort and provides a comparison between the validation
and test sets. There was no significant difference in any character-
istic between the two sets.
Risk factors for POPF
The results of the univariable analysis on the modelling set are
reproduced in Tables 2 and 3 and the results of the multivariable
analysis in Table 4. The resulting model contained BMI (P =
0.011) and pancreatic duct width (P < 0.001). A risk score derived
from this model to predict the likelihood of POPF is calculated
thus:
exp . . .
exp
− + [ ]− [ ]( )
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1 3
BMI pancreatic duct width mm
. . .206 0 107 0 404+ [ ]− [ ]( ){ }BMI pancreatic duct width mm
Confidence intervals (95% CIs) can be calculated as follows:
lower CI = (risk score*0.814) − 2, and upper CI = (risk score*1.110)
+ 5.7. An ROC curve was produced to test the accuracy of this risk
score in predicting POPF (Fig. 1). The area under the ROC curve
was found to be 0.832 (95% CI 0.768–0.897; P < 0.001).
In order to validate the risk score, it was applied to the valida-
tion set. The area under the ROC curve for the validation set was
found to be 0.751 (95% CI 0.649–0.852), which did not differ
significantly from the area under the ROC curve for the modelling
set (P = 0.241).
Figure 2 further evaluates the performance of the risk score.
Patients in the modelling set were divided into deciles based on
their risk scores. Patients in the validation set were then divided
into quintiles because there were fewer patients in this set. The
observed rate of pancreatic leaks was then calculated for each of
the percentiles and plotted at the mean value within each interval.
A reference line was added to indicate where the points would lie
if the risk score had performed perfectly. As Fig. 2 shows, the
plotted points are close to this line, a further indication of the
accuracy of the risk score. Figure 3 demonstrates graphically
the risk for POPF relative to BMI and pancreatic duct width as
predicted by the score. Thus, obese patients (BMI: 30–35 kg/m2)
with a narrow duct (< 3 mm in diameter) have a 30–55% risk for
developing POPF, whereas patients with a pancreatic duct diam-
eter of >10 mm, regardless of BMI, have a risk of <5%.
A web-based calculator for this risk score is available at http://
www.uhb.nhs.uk/preoperative-prediction-of-pancreatic-fistula-
calculator.htm.
Table 1 Characteristics of the whole group and patients in the modelling and validation sets. There was no significant difference in any
characteristic between the modelling and validation sets
Whole group
(n = 325)
Modelling set
(n = 217)
Validation set
(n = 108)
P-value
Age, years, median (IQR) 67 (61–73) 67 (60–73) 68 (61–72) 0.955
Gender, male, n (%) 182 (56.3%) 120 (55.8%) 62 (57.4%) 0.812
BMI, kg/m2, median (IQR) 24.9 (22.5–27.8) 25.0 (22.5–27.8) 24.6 (22.6–27.8) 0.952
Smoker, n (%) 53 (16.3%) 33 (15.2%) 20 (18.5%) 0.651
Preoperative diabetes, n (%) 46 (14.2%) 31 (14.3%) 15 (13.9%) 1.000
Diagnosis, n (%)
Pancreatic adenocarcinoma 128 (39.4%) 88 (40.6%) 40 (37.0%) 0.169
Cholangiocarcinoma 47 (14.5%) 33 (15.2%) 14 (13.0%)
Ampullary carcinoma 68 (20.9%) 40 (18.4%) 28 (25.9%)
Duodenal carcinoma 20 (6.2%) 11 (5.1%) 9 (8.3%)
Neuroendocrine tumour 15 (4.6%) 10 (4.6%) 5 (4.6%)
Benign 22 (6.8%) 16 (7.4%) 6 (5.6%)
Other 25 (7.7%) 19 (8.8%) 6 (5.6%)
PPPD/Whipple procedure, n 294/31 193/24 101/7 0.231
PJ/PG, n 176/149 117/100 59/49 0.907
Pancreatic fistula, n (%)
(ISGPF Grade A/B/C)
77 (23.7%)
(29/28/20)
48 (22.1%)
(21/19/8)
29 (26.9%)
(8/9/12)
0.420
IQR, interquartile range; BMI, body mass index; PPPD, pylorus-preserving pancreaticoduodenectomy; PJ, pancreaticojejunostomy; PG,
pancreaticogastrostomy; ISGPF, International Study Group on Pancreatic Fistula.
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Associations between severity of POPF and
independent variables
The associations between ISGPF grade, pancreatic duct width and
BMI were explored in the whole cohort. There was no significant
difference in pancreatic duct width or BMI between patients with
POPF of ISGPF Grade A and those with Grade B or C POPF
(Table 5).
Interobserver variation in data derived from
CT measurements
There was generally strong correlation between reviewers’ obser-
vations of preoperative CT imaging. Assessments of pancreatic
duct width by the surgeon and hepatobiliary radiologist produced
an intraclass correlation of 0.831 and a mean ± [2 × standard
errors of the mean (SEM)] difference of 0.48 ± 0.51 mm.
Discussion
This study reviewed various factors associated with the occurrence
of POPF following PD with the aim of developing a preoperative
score predictive of POPF. Variables identified intra- or postopera-
tively were purposefully excluded from analysis. The main find-
ings were that BMI and pancreatic duct width independently
correlated (positively and negatively, respectively) with POPF.
These results were used to construct a statistical model to predict
risk for POPF. The utility of this score was validated successfully in
a separate cohort of patients.
This is not the first study to develop a predictive score for POPF.
Gaujoux et al. identified that BMI, pancreatic steatosis and an
absence of pancreatic fibrosis were independently associated with
POPF.14 The index derived in that study was based upon the
presence or absence of these categorical variables and gave a score
of 0–3. Callery et al. reported a well-conducted study that used
four variables to construct a score with four categorical risks for
POPF.24 The variables were an assessment of pancreatic texture
(firm or soft), pancreatic duct width, pathology and intrao-
perative blood loss. Yamamoto et al. developed a risk score based
upon preoperative variables and included five factors yielding a
score of 0–7.25 This latter score and the present score share a clear
Table 2 Univariate analysis of continuous factors in the modelling set (n = 217)
Factor n Pancreatic fistula a P-value
No Yes AUROC (SE)
Patient factor
Age, years, median (IQR) 217 66.7 (59.8–73.4) 66.9 (60.7–73.3) 0.502 (0.047) + 0.961
BMI, kg/m2, median (IQR) 211 24.7 (22.0–27.0) 26.8 (24.0–32.4) 0.677 (0.045) + < 0.001
Biochemical result, median (IQR)
White cell count, ×109/l 216 7.70 (6.60–9.80) 7.90 (6.63–9.48) 0.508 (0.046) − 0.865
Platelet count, ×109/l 216 306 (244–395) 297 (237–342) 0.552 (0.046) − 0.271
Haemoglobin, g/dl 216 12.6 (11.7–13.5) 12.6 (11.0–13.7) 0.506 (0.051) − 0.901
International normalized ratio 212 1.00 (1.00–1.10) 1.00 (0.90–1.10) 0.516 (0.049) − 0.743
Aspartate transaminase, IU/l 209 52.0 (28.0–84.5) 32.0 (21.3–69.5) 0.598 (0.048) − 0.039
Alanine transaminase, IU/l 48 50.0 (30.3–140.3) 40.0 (15.8–118.8) 0.559 (0.115) − 0.568
Alkaline phosphatase, IU/l 216 558 (280–955) 293 (193–672) 0.630 (0.047) − 0.006
Sodium, mmol/l 216 139 (136–142) 140 (138–142) 0.548 (0.045) + 0.308
Potassium, mmol/l 213 4.30 (3.90–4.60) 4.20 (3.90–4.47) 0.529 (0.046) − 0.534
Urea, mmol/l 216 5.20 (4.30–6.68) 5.70 (4.63–7.10) 0.558 (0.047) + 0.220
Creatinine, μmol/l 216 75.0 (64.0–92.8) 78.5 (66.8–98.5) 0.567 (0.048) + 0.157
Bilirubin, μmol/l 216 39.5 (14.0–130.0) 14.0 (6.0–50.0) 0.659 (0.047) − 0.001
Albumin, g/l 216 41.0 (38.0–44.0) 41.0 (38.0–43.0) 0.502 (0.046) − 0.969
Neutrophil count, ×109/l 216 5.00 (3.80–6.60) 5.30 (4.25–6.35) 0.523 (0.045) + 0.632
Lymphocyte count, ×109/l 216 1.90 (1.40–2.40) 1.85 (1.30–2.45) 0.519 (0.047) − 0.687
Neutrophil : lymphocyte ratio 216 2.74 (1.91–4.00) 3.29 (1.66–4.85) 0.518 (0.049) + 0.711
Data from CT imaging, median (IQR)
Pancreas width, mm 217 14.9 (12.7–17.8) 17.2 (14.3–20.0) 0.644 (0.044) + 0.002
Pancreas duct diameter, mm 217 4.90 (1.75–7.15) 0.00 (0.00–1.47) 0.801 (0.033) − < 0.001
Renal fat thickness, mm 217 10.0 (4.5–16.1) 11.5 (6.3–18.8) 0.581 (0.046) + 0.086
Superficial fat thickness, mm 217 13.0 (9.0–19.3) 14.2 (9.2–24.0) 0.552 (0.048) + 0.276
a+ or − indicates a positive or negative association with pancreatic fistula, respectively.
AUROC, area under the receiver operating characteristic curve; SE, standard error; IQR, interquartile range; BMI, body mass index; CT, computed
tomography.
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advantage as they can be applied in the preoperative phase, but
only the present study uses continuous data and presents a
patient’s risk as a continuous value. Considering the pancreatic
duct width as a binary outcome greatly limits the ability of this
variable to predict POPF risk. Furthermore, recording a patient’s
BMI and pancreatic duct width is easy and reproducible. The
score reported by Yamamoto et al.25 requires four measurements
from CT imaging. The strong correlation between the interpreta-
tion of data obtained from CT imaging by the surgeon and
hepatobiliary radiologist in the present study demonstrates that
this risk assessment can be carried out by the surgeon in the
outpatient setting.
A preoperative score predictive of POPF clearly cannot include
characteristics of the gland that are identified intra- or postopera-
tively, some of which are strongly associated with POPF. These
include the histological assessment of pancreatic steatosis14,17,18
and fibrosis,14,18 a soft or hard gland at palpation16,24,26–28 and
pancreatic duct width.22–24 Increasing evidence, however, indicates
that an indirect assessment of the gland is possible. Fatty pancreas,
first described in 1933,29 is associated with obesity14,17 and a local
inflammatory state, so-called non-alcoholic pancreatic disease.30
The association between obesity and pancreatic disease has only
recently been appreciated and an increased BMI associated with
POPF following PD14,31 and distal pancreatectomy.32 Hepatic
steatosis, related to increased BMI, is reliably assessed by measur-
ing hepatic density in non-contrast CT imaging.33,34 A recent study
assessed the utility of CT imaging to indirectly assess pancreatic
density as a surrogate for steatosis and the relationship with
POPF; a significant association was identified.20 In the present
study, preoperative CT scans for over 75% of patients did not
include a non-contrast CT sequence. It was therefore not possible
Table 3 Univariate analysis of categorical factors in the modelling
set (n = 217)
Factor n Rate of
leaks
P-valuea
Sex 1
Male 120 21.7%
Female 95 22.1%
Pathological diagnosisb < 0.001
Pancreatic carcinoma/
cholangiocarcinoma/ampullary
carcinoma
167 17.4%
Duodenal carcinoma 16 62.5%
Benign disease/neuroendocrine
tumour/other disease
34 26.5%
Operation 0.434
Pylorus-preserving
pancreaticoduodenectomy
193 21.2%
Whipple procedure 24 29.2%
Pancreatic reconstruction 0.140
Pancreaticojejunostomy 117 17.9%
Pancreaticogastrostomy 100 27.0%
Smoker 0.042
Non-smoker 108 24.1%
Ex-smoker 66 25.8%
Current smoker 33 6.1%
Preoperative diabetes 0.842
No 180 21.7%
Type 1 5 20.0%
Type 2 26 26.9%
aFisher's exact test.
bBecause of the number of different pathological diagnoses, some were
grouped together. Patients with pancreatic adenocarcinoma, ampullary
carcinoma and cholangiocarcinoma had similar rates of pancreatic fistula
(PF) as did those with other diseases, neuroendocrine tumours and
benign disease.
Table 4 Multivariate backwards stepwise logistic regression model on the data in the modelling set (n = 217)
Factor Coefficient Odds ratio (95% CI) P-value
Constant −3.026 0.049 0.01
Body mass index 0.107 1.113 (1.025–1.209) 0.011
Pancreatic duct width −0.404 0.668 (0.568–0.786) <0.001
95% CI, 95% confidence interval.
Figure 1 Receiver operating characteristic curve of risk score in the
modelling set
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to assess pancreatic density as determined by CT analysis in this
study.
Pancreatic steatosis can be assessed using other radiological
modalities, including magnetic resonance imaging (MRI),35–37
magnetic resonance spectroscopy38,39 and endoscopic ultra-
sound.40 The clinical application of these techniques is limited by
their infrequent use; for example, fewer than 10% of patients
undergoing PD are assessed by MRI.41
Quantifying a patient’s risk for POPF prior to PD is essential if
the clinician is to provide individualized care to a patient consid-
ered for PD because POPF is responsible for the majority of mor-
bidity and mortality following this procedure. The data presented
in this study demonstrate that an individual’s risk for POPF can
vary from <1% to >50% based upon considerations of BMI and
pancreatic duct width alone. Elucidating a patient’s risk for POPF
has several advantages. Preoperative consent and counselling can
Figure 2 Comparison between the scoring system and observed rates of postoperative pancreatic fistula (POPF). The performance of the
risk score in both the modelling and validation cohorts is demonstrated with the actual observed rate of POPF; bars represent 95%
confidence intervals (CIs). There were twice as many patients within the modelling group (divided into deciles) as the validation group
(divided into quintiles). The solid line indicates the perfect performance of the score; the dashed lines indicate the 95% CI
Figure 3 Graphical representation of risk for postoperative pancreatic fistula (POPF) as predicted by the risk score. Pancreatic duct width
was measured from preoperative computed tomography imaging. BMI, body mass index
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be tailored to each patient. The selection of patients and operative
technique can be optimized as it is in patients with borderline
fitness and those with lesions of uncertain pathological behaviour.
For example, the decision to undertake partial or total pancreatic
resection in a patient with an intraductal papillary mucinous neo-
plasm may be influenced by the risk for POPF, and a patient with
a cystic lesion of the head of the pancreas that is deemed to be
benign but is associated with a risk for malignant transformation
in the future is likely to be influenced into pursuing conservative
or surgical treatment depending upon his or her risk for POPF.
Patients with proven malignant disease are unlikely to decline PD
if they are deemed to be at high risk for POPF, but their clinical
management may vary. Patients at low risk for POPF may benefit
from the early removal of abdominal drains and/or the instigation
of enteral feeding. Those at high risk may benefit from the place-
ment of a feeding jejunostomy at the time of PD as the incidence
of infective complications is lower than with parenteral nutrition,
and complications with tube obstruction or dislodgement are
lower than with nasojejunal feeding.42 Finally, trials of operative or
therapeutic interventions aimed at decreasing rates of POPF have
largely failed to demonstrate clinical benefit. Studies may now be
designed to target those patients with the highest degree of risk for
POPF.
It can be argued that ISGPF Grade A fistulae are not clinically
relevant and therefore should not be considered as representing an
important complication. There was no significant difference in
either pancreatic duct width or BMI between patients with Grade
A POPF and those with Grade B or C POPF. Both of these factors
independently predispose to POPF as defined by an amylase-rich
drain effluent, but whether other unidentified factors influence
which patients will develop clinically relevant POPF is unclear and
warrants further investigation. All factors analysed in this study
were used to discriminate between patients who developed Grade
A POPF and those who developed Grade B or C POPF; however,
no significant factor was identified (data not shown). There are
theoretical advantages to measuring visceral fat rather than BMI.
Visceral fat can be regarded as a metabolic organ in its own right,
in comparison with superficial fat, and is associated with meta-
bolic syndrome,43 which, in turn, has been associated with fatty
pancreas.38,44,45 Tranchart et al. reviewed the potential role of the
visceral fat area (VFA) in predicting POPF.46 In non-contrast CT
images, the VFA emerged as an independent predictor of Grade B
and C POPF in comparison with no POPF and Grade A POPF.46
However, Tranchart et al. observed that the BMI of patients with
Grade B or C POPF was significantly different from that of
patients without POPF or with Grade A POPF, presumably in
keeping with the VFA findings.46 This lack of correlation between
BMI and the occurrence of Grade A POPF differs from the find-
ings of the present study; furthermore, assessing the VFA is more
complex than the technique used in the present study and requires
additional software and training.46 In addition, the area under the
ROC curve generated from the predictive score in the present
study (0.832) is higher than that obtained by Tranchart et al.46
using VFA alone (0.77), which indicates the former’s greater sen-
sitivity and specificity in the prediction of POPF. In another study,
retro-renal fat thickness was associated with POPF,21 but this was
not observed in the present cohort or by Tranchart et al.46
Although there is some conflict among the data regarding which
assessment of body fat is most useful in predicting POPF, there is
overwhelming evidence for the association of obesity with POPF.
Whether obesity and its relation to risk for POPF are most opti-
mally assessed by physical characteristics such as BMI, radiologi-
cal characteristics such as VFA or possibly pancreatic density or
the pathological assessment of the resected gland remains to be
elucidated. The advantage of using BMI is that it is the easiest
characteristic to measure and is available in the preoperative
period.
The other component of the predictive score is pancreatic duct
width. Its negative association with POPF has been observed pre-
viously.16,22,23 Others have considered pancreatic duct width as a
binary variable and refer to it as either normal or wide. Consid-
ering duct width as a continuous variable makes it possible to
identify risk for POPF with much greater predictive accuracy.
In conclusion, this study has developed a score predictive of
POPF based solely upon preoperative information, which is simple
and quick to use and has been validated within a separate cohort of
patients. An individualized assessment of risk for POPF enhances
preoperative counselling and patient selection for PD. Further-
more, the stratification of risk may permit a change to established
clinical practice and facilitate research into risk factors for and
strategies to decrease POPF amongst those patients at highest risk.
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